Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation
Michael J. Primiano, Bruce A. Lefker, Michael Bowman, et al.
The Journal of Immunology (2016) Vol. 197, Iss. 6, pp. 2421-2433
Open Access | Times Cited: 162

Showing 1-25 of 162 citing articles:

Targeting the NLRP3 inflammasome in inflammatory diseases
Matthew Mangan, Edward J. Olhava, William Roush, et al.
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 8, pp. 588-606
Closed Access | Times Cited: 1547
MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition
Rebecca C. Coll, James R. Hill, Christopher J. Day, et al.
Nature Chemical Biology (2019) Vol. 15, Iss. 6, pp. 556-559
Open Access | Times Cited: 748
New insights into acute pancreatitis
Peter J. Lee, Georgios I. Papachristou
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 8, pp. 479-496
Closed Access | Times Cited: 679
Pharmacological Inhibitors of the NLRP3 Inflammasome
Ayesha Zahid, Bofeng Li, Arnaud John Kombe Kombe, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 563
Inflammation in gout: mechanisms and therapeutic targets
Alexander So, Fabio Martinon
Nature Reviews Rheumatology (2017) Vol. 13, Iss. 11, pp. 639-647
Open Access | Times Cited: 455
MCC950 closes the active conformation of NLRP3 to an inactive state
Ana Tapia‐Abellán, Diego Angosto-Bazarra, Helios Martínez‐Banaclocha, et al.
Nature Chemical Biology (2019) Vol. 15, Iss. 6, pp. 560-564
Open Access | Times Cited: 366
The NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Li Wang, Arthur V. Hauenstein
Molecular Aspects of Medicine (2020) Vol. 76, pp. 100889-100889
Closed Access | Times Cited: 326
The role of inflammasomes in kidney disease
Takanori Komada, Daniel A. Muruve
Nature Reviews Nephrology (2019) Vol. 15, Iss. 8, pp. 501-520
Closed Access | Times Cited: 253
MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice
Agampodi Promoda Perera, Ruchira Fernando, Tanvi Shinde, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 251
Cell death pathways: intricate connections and disease implications
Matthias Kist, Domagoj Vucic
The EMBO Journal (2021) Vol. 40, Iss. 5
Open Access | Times Cited: 243
The NLRP3 and Pyrin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases
Carlos de Torre‐Minguela, Pablo Mesa-del-Castillo, Pablo Pelegrı́n
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 220
Severe COVID-19: NLRP3 Inflammasome Dysregulated
Daan F. van den Berg, Anje A. te Velde
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 209
Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3
Inga V. Hochheiser, Michael Pilsl, Gregor Hagelueken, et al.
Nature (2022) Vol. 604, Iss. 7904, pp. 184-189
Open Access | Times Cited: 197
Therapeutic modulation of inflammasome pathways
Dhruv Chauhan, Lieselotte Vande Walle, Mohamed Lamkanfi
Immunological Reviews (2020) Vol. 297, Iss. 1, pp. 123-138
Open Access | Times Cited: 173
Microneedle-assisted genome editing: A transdermal strategy of targeting NLRP3 by CRISPR-Cas9 for synergistic therapy of inflammatory skin disorders
Tao Wan, Qi Pan, Ping Yuan
Science Advances (2021) Vol. 7, Iss. 11
Open Access | Times Cited: 154
P2X7 receptor and the NLRP3 inflammasome: Partners in crime
Pablo Pelegrı́n
Biochemical Pharmacology (2020) Vol. 187, pp. 114385-114385
Closed Access | Times Cited: 150
Innate Immune Cell Death in Neuroinflammation and Alzheimer’s Disease
Y. Rajesh, Thirumala‐Devi Kanneganti
Cells (2022) Vol. 11, Iss. 12, pp. 1885-1885
Open Access | Times Cited: 150
Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950
Sarah E. Corcoran, Reena Halai, Matthew A. Cooper
Pharmacological Reviews (2021) Vol. 73, Iss. 3, pp. 968-1000
Open Access | Times Cited: 120
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets
Lieselotte Vande Walle, Mohamed Lamkanfi
Nature Reviews Drug Discovery (2023) Vol. 23, Iss. 1, pp. 43-66
Closed Access | Times Cited: 120
Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome
Hao Li, Yanling Guan, Bo Liang, et al.
European Journal of Pharmacology (2022) Vol. 928, pp. 175091-175091
Closed Access | Times Cited: 106
Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction
Qiang Ma
Pharmacological Reviews (2023) Vol. 75, Iss. 3, pp. 487-520
Open Access | Times Cited: 93
Structural basis for the oligomerization-mediated regulation of NLRP3 inflammasome activation
Umeharu Ohto, Yukie Kamitsukasa, Hanako Ishida, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 11
Open Access | Times Cited: 87
Mechanisms of PANoptosis and relevant small-molecule compounds for fighting diseases
Lian Wang, Yanghui Zhu, Lu Zhang, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 12
Open Access | Times Cited: 48
NLRP3 inflammasome signalling in Alzheimer's disease
Róisín M. McManus, Eicke Latz
Neuropharmacology (2024) Vol. 252, pp. 109941-109941
Open Access | Times Cited: 30
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors
Juraj Velcicky, Philipp Janser, Nina Gommermann, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 2, pp. 1544-1562
Closed Access | Times Cited: 24
Page 1 - Next Page

Scroll to top